Answers are grounded in this paper and cite their sources.
Purpose: The purpose of this study was to describe cases of corneal melt associated with systemic cancer immunotherapy. Methods: This is a case series of 6 patients. Results: Corneal melt was noted in all eyes, including 1 patient on an epidermal growth factor receptor (EGFR) inhibitor and another on a human epidermal growth factor 2 (HER2) inhibitor that resolved on serum tears; 1 patient on a fibroblast growth factor receptor (FGFR) inhibitor that stabilized on serum tears and amniotic membrane; 1 patient on a Bruton tyrosine kinase (BTK) inhibitor and another on a breakpoint cluster region protein-abelson murine leukemia viral oncogene homolog 1 (BCR-ABL) inhibitor that both had corneal thinning with perforation; and 1 patient with bilateral corneal thinning complicated by a fungal superinfection after long-term use of a programmed cell death protein 1 (PD-1) inhibitor. Conclusions: While primarily described with EGFR inhibitors, corneal melt may present with vision-threatening consequences in other classes of cancer immunotherapy including FGFR inhibitors, PD-1 inhibitors, and other tyrosine kinase inhibitors.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: